Back to Authors

Flitton, Chloe

https://orcid.org/0009-0005-2778-8381

Mayo Clinic

University of Dundee

Citations 1

PPM1M, a LRRK2-counteracting, phosphoRab12-preferring phosphatase with potential link to Parkinson’s disease
Chiang, Claire Y , Pratuseviciute, Neringa , Lin, Yu‐En , Adhikari, Ayan , Yeshaw, Wondwossen M , Flitton, Chloe , Sherpa, Pemba , Tonelli, Francesca , Lynch, Timothy , Siuda, Joanna , Pulyk, O. R. , Sherpa, Pemba L , Rektorova, Irena , Lynch, Timothy , Siuda, Joanna S. , Pulyk, Oleksandr , Bauer, Peter , Beetz, Christian , Dickson, Dennis W , Ross, Owen A , Wszolek, Z.K. , Klein, Christine , Zimprich, Alexander , Alessi, Dario R , Sammler, Esther M , Pfeffer, Suzanne R , Tonelli, Francesca , Rektorová, Irena , Rudzińska, Monika , Dickson, Dennis W. , Ross, Owen A. , Wszołek, Zbigniew K. , Klein, Christine , Zimprich, Alexander , Alessi, Dario R. , Sammler, Esther

No container title available | March 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.19.644182 Get It

Abstract Leucine-rich repeat kinase 2 (LRRK2) phosphorylates a subset of Rab GTPases that regulate receptor trafficking; activating mutations in LRRK2 are linked to Parkinson’s disease. Rab phosphorylation is a transient event that can be reversed by phosphatases, including PPM1H, that acts on phosphoRab8A and phosphoRab10. Here we report a phosphatome-wide siRNA screen that identified PPM1M as a phosphoRab12-preferring phosphatase that also acts on phosphoRab8A and phosphoRab10. Upon knockout from cells or mice, PPM1M displays selectivity for phosphoRab12. As shown previously for mice harboring LRRK2 pathway mutations, knockout of Ppm1m leads to primary cilia loss in striatal cholinergic interneurons. We have also identified a rare PPM1M mutation in patients with Parkinson’s disease that is catalytically inactive when tested in vitro and in cells. These findings identify PPM1M as a key player in the LRRK2 signaling pathway and provide a new therapeutic target for the possible benefit of patients with Parkinson’s disease. Teaser Parkinson’s linked Rab phosphorylation is reversed by PPM1M; the inactive D440N variant is implicated in rare patient cases.